Total Results: 228
The Government Accountability Office said it will investigate potential abuses of the orphan drug program, which offers incentives to drugmakers to develop medicines for rare diseases.
Experts say the surge in reports could indicate a growing number of harmed patients or more vigilant reporting of adverse events. In other public health news: childbirth, chronic diseases, telehealth and a rare version of strep throat.
From the Food and Drug Administration and the National Institutes of Health to Meals on Wheels, news outlets cover the impact that the proposed Trump administration budget cuts would have on a range of health care organizations and initiatives.
Spending on consumer advertising by drugmakers has increased 62 percent since 2012.
Por primera vez, una investigación muestra que un nuevo, y costoso, medicamento llamado Repatha no sólo baja dramáticamente los niveles de colesterol malo (LDL) sino que también reduce el riesgo de ser hospitalizado y de morir.
A selection of opinions on health care from around the nation.
Scientists and industry speak out about President Donald Trump’s proposed cuts to health spending.
A cholesterol-lowering drug called Repatha cuts the risk of heart attacks, strokes and heart-related death by 20 percent, according to a new study.
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
News outlets report on stories related to pharmaceutical drug pricing.
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
The numbers show that President Trump’s choice for FDA commissioner, Scott Gottlieb, has long-standing ties to pharmaceutical companies as a board member or consultant and that he had to recuse himself multiple times while working at the FDA.
The popular measures undermine a more thoughtful federal program that balances patients’ need for options, drug companies’ desire to protect their investments, and the government’s duty to evaluate drug safety and effectiveness, they say.
Scott Gottlieb, a physician who left the Food and Drug Administration in 2007, is a consultant to GlaxoSmithKline’s product investment board; a managing director at T.R. Winston & Company merchant bank, which specializes in health care; and a clinical assistant professor at New York University School of Medicine.
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
A selection of opinions on health care from around the country.
In other news on pharmaceutical costs, Sen. Chuck Grassley (R-Iowa) questions Kaleo about the $4,500 price tag of its EpiPen alternative and some payers are denying coverage of pricey hepatitis C treatments, despite more discounts.
Reps. Elijah Cummings (D-Md.) and Peter Welch (D-Vt.), who plan to introduce related legislation in two to three weeks, met privately with President Donald Trump to discuss this strategy to control drug costs.
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
Read recent commentaries about drug-cost issues.